Renal Unit, KEM Hospital, Pune, India.
GenePath Laboratories, Pune, India.
Nephrology (Carlton). 2022 Mar;27(3):231-237. doi: 10.1111/nep.14004. Epub 2021 Dec 7.
Pregnancy-associated hemolytic uremic syndrome (P-aHUS) is an important cause of peripartum acute kidney injury. Studies from Europe have described mutations in complement regulator genes, and data in Indian patients is scarce. Hence this study used multiplex ligation-dependent probe amplification (MLPA) to identify variants in complement genes in P-aHUS patients.
We present 17 patients of P-aHUS who were investigated for complement protein levels and genetic analysis with MLPA for complement genes. Plasma exchange therapy was offered to all patients presenting in acute phase.
Mean age 26.74 (3.36) years with 15/17 delivered by caesarean section. Eleven patients received early (within 7 days) plasma exchange, three were dialysis-dependent at 3 months and seven were dialysis-free. Only one of the three patients receiving late (after 7 days) plasma exchange was dialysis-free. MLPA showed that 11 patients had heterozygous deletions of exons 3, 5, 6 of CFHR1 and upstream region of exons 1, 2, 3, 6 and intron 4 of CFHR3 gene while four patients had homozygous deletions at the same loci. Two patients had no MLPA-detectable variations.
This study reports a high proportion of deletions of exons of CFHR1 & CFHR3 genes in Indian P-aHUS patients detectable by MLPA by copy number variations. This needs confirmation in large multicentre studies. Plasma exchange can be an effective therapy in the non-availability of Eculizumab.
妊娠相关性溶血尿毒综合征(P-aHUS)是围产期急性肾损伤的重要原因。来自欧洲的研究描述了补体调节基因的突变,而印度患者的数据则很少。因此,本研究使用多重连接依赖性探针扩增(MLPA)来鉴定 P-aHUS 患者补体基因中的变异。
我们报告了 17 例 P-aHUS 患者,对其进行了补体蛋白水平检测,并通过 MLPA 对补体基因进行了遗传分析。所有在急性期出现的患者均接受了血浆置换治疗。
平均年龄为 26.74(3.36)岁,17 例患者中有 15 例经剖宫产分娩。11 例患者接受了早期(7 天内)血浆置换治疗,3 例患者在 3 个月时需要透析,7 例患者不需要透析。仅 1 例接受晚期(7 天后)血浆置换的患者无需透析。MLPA 显示 11 例患者 CFHR1 基因外显子 3、5、6 和 CFHR3 基因外显子 1、2、3、6 和内含子 4 的上游区域存在杂合性缺失,4 例患者在相同位置存在纯合性缺失。2 例患者没有 MLPA 可检测到的变异。
本研究报告了印度 P-aHUS 患者 CFHR1 和 CFHR3 基因外显子缺失的比例较高,这可以通过 MLPA 检测到拷贝数变异。这需要在大型多中心研究中进行证实。在没有 Eculizumab 的情况下,血浆置换可以是一种有效的治疗方法。